Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
Voxzogo given green-light to treat children under five by US FDA –
At present Voxzogo is currently marketed in the European Union in children with achondroplasia who are 2 years of age and older with open growth